Chronic Myeloid Leukemia

Chronic Myeloid Leukemia (CML) stands out in cancer research due to the groundbreaking targeted therapy it has inspired. With the discovery of the BCR-ABL fusion gene as its hallmark, researchers developed tyrosine kinase inhibitors (TKIs) like imatinib, revolutionizing treatment. Despite TKIs' effectiveness, challenges persist, including drug resistance and long-term side effects. Ongoing studies explore novel therapeutic approaches, including combination therapies and immunotherapies, aiming for deeper and more durable responses. Additionally, efforts focus on identifying biomarkers for predicting treatment response and monitoring disease progression. The success story of CML research underscores the potential of precision medicine in cancer treatment, offering hope for improved outcomes and quality of life for patients.